LL-37

LL-37 is a naturally occurring, 37-amino-acid human antimicrobial peptide derived from the C-terminal region of the precursor protein hCAP18, encoded by the CAMP gene. It belongs to the cathelicidin family and plays important roles in innate immune defense, epithelial barrier function, inflammation, and tissue repair. LL-37 is cationic and amphipathic, allowing it to interact with microbial membranes. Beyond direct antimicrobial activity, it influences immune-cell recruitment, inflammatory signaling, angiogenesis, and epithelial migration. The peptide is found in neutrophils and several epithelial tissues, including the skin and respiratory tract. Its effects are strongly influenced by local concentration, tissue environment, and underlying disease.

LL-37 has substantial laboratory and animal evidence involving bacteria, fungi, biofilms, inflammatory pathways, and wound repair. It has also undergone randomized human testing as a topical treatment for venous leg ulcers. An initial 34-person study reported encouraging healing responses at selected concentrations, but a subsequent phase IIb trial involving 149 randomized participants did not demonstrate a statistically significant benefit in the overall study population, although exploratory findings in larger ulcers suggested a possible treatment effect. Limited clinical evidence does not mean there is no evidence: LL-37 has meaningful human and preclinical research, but it is not an approved systemic antimicrobial, immune-enhancement, or wound-healing treatment. Excess LL-37 signaling has also been implicated in psoriasis, rosacea, and certain autoimmune and inflammatory pathways. No FDA-approved LL-37 medication or validated human injectable regimen exists.

Understanding LL-37: Antimicrobial Defense and Context-Dependent Immune Signaling

LL-37 is multifunctional. It can act directly on microbial membranes, interact with microbial and host nucleic acids, and influence several cellular signaling pathways. Its actions depend heavily on concentration, local conditions, and tissue type.

1. CAMP Gene

The human CAMP gene encodes the precursor protein hCAP18, from which LL-37 is generated by proteolytic processing.

2. hCAP18 Processing

Enzymes including proteinase 3 contribute to the generation of LL-37 from its larger precursor in appropriate physiological contexts.

3. Human Innate Immunity

LL-37 participates in the first-line defense system that responds to microbes before an antigen-specific adaptive immune response develops.

4. Cationic Structure

Its positively charged residues favor interactions with negatively charged bacterial membrane components and other biological molecules.

5. Amphipathic Alpha Helix

LL-37 can adopt a structure with hydrophobic and hydrophilic regions that facilitates membrane interactions.

6. Bacterial Membrane Disruption

Under appropriate experimental conditions, LL-37 can alter microbial membrane integrity, permeability, and cellular viability.

7. Gram-Negative Bacteria

LL-37 has laboratory activity against selected Gram-negative organisms, but potency varies substantially with bacterial species and environmental conditions.

8. Gram-Positive Bacteria

Laboratory activity also extends to selected Gram-positive organisms, including Staphylococcus aureus under certain conditions.

9. Salt and Serum Sensitivity

Antimicrobial potency can change with salt concentration, serum components, proteases, and interactions with host molecules.

Consequently, laboratory antimicrobial activity does not guarantee effectiveness in blood or infected tissue.

10. Biofilm Research

LL-37 has been studied for effects on microbial attachment and biofilm development.

Effects vary by organism and concentration, and some low-exposure conditions may produce undesirable responses.

11. Fungal Interactions

Experimental research demonstrates interactions with selected fungi, including Candida species.

12. Viral Research

LL-37 can interact with certain viruses or host antiviral responses in experimental systems.

It is not an established treatment for viral infections.

13. Lipopolysaccharide Binding

LL-37 can interact with bacterial lipopolysaccharide and influence its ability to activate inflammatory signaling.

14. Immune-Cell Recruitment

LL-37 can influence migration of selected leukocytes and other immune cells.

15. FPR2 Signaling

Formyl peptide receptor 2 has been implicated in certain LL-37-related cellular migration and signaling responses.

LL-37 should not be described as acting exclusively through FPR2.

16. P2X7-Related Activity

Experimental research has implicated purinergic receptor-associated pathways in selected LL-37 inflammatory responses.

17. Toll-Like Receptor Signaling

LL-37 can interact with nucleic acids and alter their recognition by innate immune receptors.

18. LL-37 and Self-DNA

LL-37 can form complexes with self-DNA that promote immune activation in particular inflammatory settings.

19. TLR9 and Psoriasis

LL-37-self-DNA complexes can stimulate plasmacytoid dendritic cells through TLR9-related pathways, contributing to psoriasis-associated immune activation.

20. Type I Interferon

Such nucleic-acid complexes can contribute to interferon signaling in experimental autoimmune and inflammatory models.

21. Rosacea

Abnormal processing or abundance of cathelicidin peptides has been implicated in rosacea-related inflammation and vascular responses.

22. Keratinocytes

LL-37 influences skin epithelial cells involved in barrier integrity and wound responses.

23. Re-Epithelialization

Laboratory and animal findings suggest effects on epithelial migration and wound closure.

24. Angiogenesis

LL-37 has demonstrated proangiogenic signaling in selected experimental models, potentially relevant to repair but also to abnormal tissue growth.

25. Tissue Concentration

Low, intermediate, and high LL-37 concentrations can produce different and sometimes opposing effects.

26. Human Wound Research

Topical application at selected concentrations has been evaluated in randomized venous leg ulcer trials, with mixed overall results.

27. Cancer Biology

LL-37 can promote proliferation or migration in some cancer models while demonstrating inhibitory or cytotoxic responses in others.

It is not a validated cancer treatment or universally protective anticancer peptide.

Mechanism Summary

Research takeaway: LL-37 is not simply an antibiotic or an immune booster. It is a multifunctional host-defense signal that can suppress certain microbial or inflammatory responses while amplifying other inflammatory pathways.

1. Antibiotic Resistance

Scientists are studying antimicrobial peptides as potential sources of new infection-control strategies.

2. Bacterial Membranes

LL-37 provides a model for studying membrane-active antimicrobial molecules.

3. Biofilms

Its effects on microbial attachment and community formation are relevant to chronic infections.

4. Wound Healing

LL-37 has human topical trial data involving chronic venous leg ulcers.

5. Diabetic Wounds

Impaired host defense and delayed healing motivate further research, although clinical LL-37 effectiveness remains unproven.

6. Skin Barrier Defense

The peptide participates in interactions among keratinocytes, microbes, and immune cells.

7. Psoriasis

LL-37 is implicated in self-DNA-driven immune activation and inflammatory amplification.

8. Rosacea

Abnormal cathelicidin processing and signaling have been implicated in characteristic skin inflammation.

9. Respiratory Host Defense

LL-37 is relevant to airway epithelial immunity and microbial interactions.

10. Cystic Fibrosis

Researchers investigate how airway conditions affect antimicrobial peptide activity.

11. Oral Health

Salivary and mucosal defense provide additional contexts for cathelicidin research.

12. Immune-Cell Communication

LL-37 interacts with pathways regulating immune-cell migration and inflammatory mediators.

13. Autoimmune Disease

Its ability to bind host nucleic acids makes it relevant to autoimmune signaling research.

14. Angiogenesis

Potential blood-vessel effects are relevant to tissue repair and cancer biology.

15. Peptide Engineering

Research seeks analogs with improved stability, reduced host-cell toxicity, or greater antimicrobial selectivity.

16. Local Drug Delivery

Topical and biomaterial-based delivery may produce different exposure and safety characteristics from systemic administration.

17. Human Clinical Translation

Mixed venous ulcer trial outcomes highlight the importance of selecting the right population, formulation, concentration, and clinically meaningful endpoint.

Research perspective: LL-37 is valuable both as a naturally occurring host-defense peptide and as a model for developing better-targeted antimicrobial and wound-healing treatments.

1. Direct Antimicrobial Activity

LL-37 can impair selected bacteria in controlled laboratory experiments.

This does not establish that administered LL-37 can cure a human infection.

2. Biofilm Modulation

Selected preclinical findings suggest effects on biofilm formation and microbial attachment.

3. Innate Host Defense

Endogenous LL-37 contributes to normal epithelial and leukocyte defense mechanisms.

4. Wound Re-Epithelialization

Experimental studies support a role in epithelial migration and repair.

5. Small Human Venous Ulcer Trial

A first-in-human study involving 34 participants reported encouraging healing measures with 0.5 and 1.6 mg/mL topical LL-37.

The 3.2 mg/mL group did not demonstrate comparable benefit.

6. Larger Phase IIb Trial

A subsequent randomized study involving 149 participants found no statistically significant healing improvement in the overall treatment population.

7. Large Venous Ulcer Subgroup

Post hoc analyses suggested possible benefit from 0.5 mg/mL in patients whose ulcers were at least 10 square centimeters.

These exploratory findings require prospective confirmation.

8. Skin Barrier Research

LL-37 participates in epithelial defense and repair-related signaling.

9. Chronic Infection Treatment

No adequate clinical trial establishes LL-37 as a substitute for antibiotics or other established antimicrobial therapies.

10. Fungal Infection Treatment

Laboratory antifungal findings do not establish clinical treatment effectiveness.

11. Antiviral Applications

Selected experimental antiviral findings remain insufficient for clinical claims.

12. Sinus and Respiratory Conditions

Airway host-defense biology is relevant, but treatment of chronic sinusitis, allergies, or respiratory infections has not been demonstrated.

13. Immune Enhancement

LL-37 does not universally strengthen immunity. Its activity may promote excessive inflammatory signaling in some contexts.

14. Psoriasis

LL-37 has been implicated in mechanisms that amplify psoriasis-related inflammation, making supplementation for psoriasis biologically uncertain.

15. Rosacea

Abnormal cathelicidin signaling contributes to rosacea-related pathways, so additional LL-37 is not an established treatment.

16. Regeneration and Longevity

No human trial establishes generalized tissue regeneration or increased lifespan.

Potential Benefits Summary

Evidence distinction: LL-37 has real human topical treatment studies, but a larger randomized trial did not meet its overall efficacy objective. Clinical claims should reflect the total evidence rather than only the promising first trial or exploratory subgroup.

Research status: LL-37 has published human topical concentrations and dose-per-wound-area exposures from randomized trials. However, no FDA-approved LL-37 dose exists, and no controlled human dose-finding trial establishes safe systemic subcutaneous, intramuscular, intravenous, oral, or intranasal administration.

Topical wound-study amounts cannot be converted into a systemic injection regimen. A topical concentration expressed in mg/mL also does not mean the patient received that many milligrams systemically.

1. Published Human Trials and Community-Reported Amounts

Critical distinction: The community amounts above are not recommendations or safe starting doses. FDA has identified significant uncertainties regarding systemic LL-37 exposure, including potential immune, reproductive, and tissue-growth risks.

2. First-in-Human Clinical Design

The first randomized clinical study included 34 adults with difficult-to-heal venous leg ulcers.

The active topical treatment phase lasted four weeks.

3. First-Trial Dose Response

The 0.5 and 1.6 mg/mL groups had more favorable healing measurements than the highest concentration group.

Clinical activity was not simply proportional to increasing concentration.

4. Phase IIb Clinical Design

The subsequent trial randomized 149 participants to topical LL-37 or placebo and included a thirteen-week treatment phase.

5. Topical Application Amount

The phase IIb protocol used 25 microliters per square centimeter of ulcer area.

At 0.5 and 1.6 mg/mL, these corresponded to 12.5 and 40 mcg/cm2, respectively.

6. Concurrent Standard Wound Care

Trial participants also received standard compression-based wound care.

Research findings cannot be attributed to LL-37 in isolation from that treatment context.

7. Subcutaneous Community Administration

Research-peptide vendors describe various injection amounts.

No adequate controlled human study establishes the subcutaneous bioavailability, pharmacokinetics, or safety of LL-37.

8. Intramuscular Administration

No approved or validated intramuscular treatment dose exists.

9. Intravenous Administration

No clinically validated IV dose or systemic safety profile exists for routine use.

10. Intranasal Administration

No adequate clinical evidence establishes nasal absorption or effective treatment concentrations for sinus or respiratory conditions.

11. Oral Administration

LL-37 is a 37-residue peptide susceptible to proteolytic processing.

No approved oral delivery system or treatment dose exists.

12. Topical Use Outside Trials

Experimental concentrations evaluated for venous ulcers are not validated for ordinary cosmetic application, acne, burns, psoriasis, or infected wounds.

13. Human Half-Life

No adequate systemic pharmacokinetic study establishes a general human LL-37 plasma elimination half-life after injection.

14. Tissue Exposure

LL-37 can interact with serum proteins, host membranes, extracellular molecules, and proteolytic enzymes.

Actual systemic bioavailability and target-tissue exposure are unknown.

15. Reconstitution

Commercial research powder is not an FDA-approved injectable drug product.

No universally validated clinical preparation instructions or in-use stability period exist for systemic administration.

16. Molecular Identity

LL-37 should be distinguished from hCAP18, engineered analogs, and shorter cathelicidin fragments.

17. Pharmaceutical Quality

• Confirm the complete 37-residue sequence.
• Verify molecular identity and peptide content.
• Assess purity and degradation.
• Characterize aggregation and biological potency.
• Evaluate the formulation's compatibility and stability.
• Use appropriate microbiological controls for clinical-grade topical or injectable research.
• Assess endotoxin content and potentially immunogenic impurities.

Dosing Summary

Research takeaway: LL-37 has legitimate numeric human topical dose data. However, these studies cannot validate systemic injections, and the larger phase IIb trial did not establish efficacy in the full population.

LL-37 has no FDA-approved therapeutic cycle or maintenance schedule. Published human research has evaluated short and intermediate periods of controlled topical application, while systemic cycling conventions remain unsupported.

1. Initial Clinical Run-In

Both major venous ulcer development studies used an initial observation or placebo run-in period with standard wound care.

2. Four-Week First Trial

The first-in-human trial used four weeks of randomized topical treatment.

3. Four-Week Initial Follow-Up

Participants underwent an additional period of follow-up after the first trial's treatment phase.

4. Thirteen-Week Phase IIb Treatment

The larger trial involved topical treatment twice weekly for thirteen weeks.

5. Sixteen-Week Follow-Up

The phase IIb study included approximately sixteen weeks of observation following treatment.

6. Acute Cell-Culture Experiments

Many mechanistic experiments examine microbial or immune-cell responses over minutes, hours, or days.

7. Animal Wound Models

Preclinical treatment periods depend on wound type and experimental design.

8. Ten-Day Community Courses

Short informal systemic injection courses are circulated online without adequate clinical validation.

9. Twenty-Day Community Courses

Longer community regimens have no established efficacy or safety advantage.

10. Four- to Eight-Week Community Use

Extended systemic protocols are not supported by controlled human pharmacology.

11. Receptor Desensitization

LL-37 has multiple biological targets. No clinical trial establishes a standard cycle to prevent receptor downregulation.

12. Washout Period

No validated systemic human elimination profile supports a particular washout interval.

13. Repeat Treatment

Repeated human courses have not been established as safe or effective for immune or infection-related goals.

14. Chronic Host-Defense Signaling

Prolonged alteration of innate immune signaling may have different consequences across tissues and disease states.

Duration Summary

Research takeaway: Four-week and thirteen-week periods have been studied in human topical wound trials, but these do not establish systemic cycling protocols or long-term immune-support regimens.

LL-37 is frequently discussed alongside antibiotics, antifungal drugs, wound-care products, and experimental repair peptides. Its strongest combination context comes from controlled topical wound research involving standard compression therapy.

1. LL-37 + Standard Compression Therapy

Both major venous ulcer trials evaluated LL-37 in addition to standard compression care.

The larger trial did not demonstrate significant improvement in the full randomized population.

2. LL-37 + Antibiotics

Laboratory research has explored how antimicrobial peptides interact with conventional antibiotics.

No general clinical antibiotic-sparing LL-37 regimen exists.

3. LL-37 + Antifungal Drugs

Antifungal activity in experimental systems does not establish improved treatment when combined with prescribed antifungals.

4. LL-37 + BPC-157

BPC-157 has separate preclinical tissue-injury research.

No controlled human trial establishes faster wound healing or improved immunity from combining it with LL-37.

5. LL-37 + TB-500

TB-500 is an inconsistently identified thymosin beta-4-related commercial substance.

Combination effects and safety depend on the exact molecular identity and remain unproven.

6. LL-37 + GHK-Cu

GHK-Cu has experimental skin and matrix-remodeling activity.

No clinical trial demonstrates synergistic wound healing from the combination.

7. LL-37 + KPV

KPV has preclinical anti-inflammatory research, while LL-37 has both antimicrobial and pro-inflammatory functions.

These differences do not establish complementary or balanced immune effects in humans.

8. LL-37 + Thymosin Alpha-1

Thymosin alpha-1 has separate immunomodulatory evidence.

Combined clinical benefits and risks are unknown.

9. LL-37 + Glutathione

Glutathione participates in cellular redox biology.

No controlled LL-37-specific synergy has been demonstrated.

10. LL-37 + Zinc

Zinc contributes to normal immune function, but additional LL-37 benefit from supplementation has not been established.

11. LL-37 + Vitamin D

Vitamin D signaling can regulate CAMP gene expression in selected cells.

This is relevant to endogenous cathelicidin biology but does not establish that high vitamin D doses or LL-37 injections improve infection resistance.

12. LL-37 + Wound Dressings

Specialized local delivery approaches may influence peptide stability and tissue exposure.

Formulation-specific results cannot be generalized to ordinary topical preparations.

13. LL-37 + Biomaterials

Hydrogels and other carriers are being investigated for localized wound delivery in experimental systems.

14. LL-37 + Other Antimicrobial Peptides

Combining membrane-active peptides may increase both antimicrobial effects and unwanted host-cell toxicity.

Appropriate controlled studies are required.

Combination Summary

Research takeaway: LL-37's best human combination evidence involves topical delivery with conventional venous ulcer care, not injectable multi-peptide immune stacks.

LL-37 has short-term human safety information from controlled topical venous ulcer trials, but no established long-term systemic human safety profile. Its endogenous origin does not mean external administration is harmless.

1. Topical Clinical Tolerability

Both major human wound trials reported generally acceptable local tolerability of the investigated topical preparations.

2. Limits of Human Safety Evidence

Safety findings from local application to ulcers cannot establish safety from systemic injection or chronic exposure.

3. Injection-Site Reactions

Pain, swelling, redness, or irritation are possible with nonapproved injectable preparations.

Reliable LL-37-specific injection event rates are not available.

4. Infection and Endotoxins

Unregulated injectable products can introduce microbial contamination or endotoxins, causing serious illness.

5. Hypersensitivity

Immune reactions to the peptide, aggregates, degradation products, or formulation components may occur.

6. Immunogenicity

FDA has identified potential immunogenicity concerns associated with compounded LL-37 preparations.

7. Host-Cell Toxicity

Membrane-active peptides may damage mammalian cells under some concentrations and experimental conditions.

8. Excess Inflammatory Signaling

LL-37 can amplify inflammatory pathways in some tissue settings rather than consistently reducing inflammation.

9. Psoriasis-Associated Immune Activation

LL-37 complexed with self-DNA can contribute to inflammatory immune activation associated with psoriasis.

10. Rosacea-Related Effects

Abnormal cathelicidin processing and signaling have been implicated in rosacea inflammation.

11. Autoimmune Responses

Nucleic-acid-associated immune stimulation raises questions about inappropriate activation in susceptible individuals.

12. Mast Cell and Vascular Effects

LL-37 can affect mast cells and vascular-related pathways in experimental systems, potentially contributing to context-dependent inflammatory effects.

13. Angiogenesis

Proangiogenic activity may be helpful in some wound settings but undesirable in others.

14. Tumor-Related Signaling

Some nonclinical studies suggest tumor-promoting effects in particular tissues, while other models show different outcomes.

There is no established human cancer incidence attributable to LL-37 administration.

15. Male Reproductive Concerns

FDA has identified nonclinical research suggesting potentially detrimental male reproductive effects.

The corresponding human risk is not adequately characterized.

16. Antimicrobial Resistance and Adaptation

Microbial responses to antimicrobial peptides vary. LL-37 should not be assumed incapable of promoting microbial adaptation or altered virulence.

17. Chronic Immune Alteration

Long-term changes in innate host-defense pathways are not adequately studied after systemic LL-37 administration.

18. Product Purity

Peptide impurities, altered sequence, aggregation, and degradation may contribute to unexpected adverse effects.

19. Unapproved Routes

Subcutaneous, intramuscular, intravenous, and intranasal use lack sufficiently characterized human clinical safety profiles.

Side Effect Summary

Warning Signs Requiring Urgent Medical Evaluation

• Breathing difficulty, facial swelling, or severe allergic symptoms.
• Fever, chills, or rapidly spreading inflammation after injection.
• Severe or worsening skin inflammation.
• Chest pain, fainting, or major systemic symptoms.
• Unexpected reproductive or persistent inflammatory symptoms following exposure.

Safety conclusion: The human topical studies offer useful short-term tolerability information, but FDA has highlighted important uncertainties involving systemic administration, immunogenicity, reproductive effects, and tissue-dependent tumor biology.

LL-37 has no approved prescribing information or established human contraindication list. The following are evidence-informed cautions rather than formal product-label contraindications.

1. Pregnancy

Reproductive and developmental safety of administered LL-37 is unknown.

2. Breastfeeding

Infant exposure and lactation safety have not been established.

3. Children and Adolescents

No validated pediatric systemic treatment or long-term safety framework exists.

4. Active Malignancy

Tissue-dependent LL-37 effects on proliferation, migration, and angiogenesis raise unresolved oncological concerns.

5. History of Cancer

Long-term safety in cancer survivors has not been adequately investigated.

6. Male Fertility Concerns

Nonclinical reproductive safety signals warrant caution.

7. Psoriasis

Excess LL-37 activity can participate in disease-associated immune activation.

8. Rosacea

Abnormal cathelicidin signaling is implicated in rosacea, so additional LL-37 is not an established treatment.

9. Autoimmune Disease

LL-37 can modulate or enhance innate immune responses in ways that may differ by condition.

10. Systemic Infections

Laboratory antimicrobial findings do not establish safe or effective treatment of systemic infection.

11. Chronic Sinus or Respiratory Infections

LL-37 is not an approved substitute for appropriate infection diagnosis and treatment.

12. Open or Chronic Wounds

Human topical trials used specific pharmaceutical preparations with standard wound care.

Research-grade material should not be presumed appropriate for direct application to open wounds.

13. Immune Suppression

Effects in immunocompromised patients remain uncertain.

14. Organ Impairment

Human pharmacokinetics and safety in severe liver or kidney disease are not established.

15. Concurrent Experimental Peptides

Interactions with other immunomodulatory, antimicrobial, or repair-related peptides have not been adequately studied.

16. Systemic Injection

Topical tolerability cannot be used to justify subcutaneous, intramuscular, or intravenous exposure.

17. Unapproved Products

Incorrect peptide identity, concentration, sterility, and purity create additional uncertainty.

18. Long-Term Immune Enhancement

No evidence supports indefinite LL-37 administration for immune optimization or infection prevention.

19. Competitive Athletics

Anti-doping classification should be checked against the current rules for nonapproved pharmacologically active substances.

Overall caution: LL-37 is a biologically active host-defense peptide that can participate in both protective and damaging inflammatory responses. It should not be regarded as a universally safe antimicrobial or immune-enhancing supplement.

LL-37 research should distinguish antimicrobial mechanisms, inflammatory signaling, wound outcomes, local tolerability, and systemic safety.

No validated biomarker panel establishes safe long-term systemic LL-37 use.

1. Peptide Identity

Confirm the exact human 37-residue sequence.

2. Purity and Stability

Assess degradation, aggregation, and peptide content.

3. Antimicrobial Activity

Laboratory experiments can measure microbial growth inhibition or killing under controlled conditions.

4. Minimum Inhibitory Concentration

MIC measurements may characterize susceptibility, but results depend on assay conditions and cannot directly establish a human treatment dose.

5. Biofilm Formation

Biofilm assays can investigate effects on bacterial attachment and community organization.

6. Host-Cell Viability

Cell viability testing is important because antimicrobial membrane activity may also affect human cells.

7. Immune-Cell Recruitment

Leukocyte migration and activation assays may clarify signaling responses.

8. NF-kappaB

Selected inflammatory transcription pathways can be assessed in appropriate cell models.

9. Cytokines

IL-1beta, IL-6, TNF-alpha, IL-8, and other mediators may be investigated depending on the model.

10. Type I Interferon

Interferon-related outcomes are relevant to LL-37 and nucleic-acid-associated immune activation.

11. TLR9

Experimental studies can assess responses to LL-37 and self-DNA complexes.

12. Mast Cell Activation

Mast cell and histamine-related responses may contribute to inflammation research.

13. Angiogenesis

Vascular signaling and new-vessel formation can be evaluated in preclinical tissue models.

14. Wound Area

Standardized wound-area measurements are central to human venous leg ulcer research.

15. Wound Healing Rate

Repeated measurements can quantify the rate of ulcer-area reduction.

16. Complete Wound Closure

Confirmed complete closure was a primary efficacy outcome in the larger randomized LL-37 trial.

17. Time to Wound Closure

Time-to-event measures help determine whether a treatment offers clinically meaningful acceleration of healing.

18. Wound Size Subgroups

Exploratory findings in ulcers at least 10 square centimeters require prospective testing in adequately powered studies.

19. Wound Infection

Clinical signs and appropriate microbiological evaluation remain important in ulcer research.

20. Histological Healing

Preclinical studies may evaluate epithelialization, inflammatory infiltration, and tissue organization.

21. Local Skin Irritation

Redness, pain, burning, dermatitis, and other local events are important topical safety outcomes.

22. Psoriasis Severity

Validated measures of lesion severity could be relevant when investigating cathelicidin-associated inflammatory biology.

23. Rosacea Severity

Clinical assessments of erythema and inflammatory lesions may provide additional research context.

24. Reproductive Safety

Future toxicology and clinical studies must assess reproductive effects suggested by nonclinical findings.

25. Tumor-Related Outcomes

Cell proliferation, invasion, angiogenesis, and long-term oncological safety require context-specific investigation.

26. Human Pharmacokinetics

Systemic absorption, distribution, degradation, clearance, and elimination half-life remain insufficiently characterized for unapproved injection routes.

27. Liver and Kidney Function

Organ-function measurements may contribute to future general systemic safety studies.

28. Immunogenicity

Immune reactions to the peptide and its impurities require further evaluation.

29. Serious Adverse Events

• Allergic reactions.
• Infections and contamination-related reactions.
• Unexpected severe inflammatory symptoms.
• Reproductive or endocrine abnormalities.
• Abnormal tissue-growth or tumor-related effects.
• Long-term organ and systemic complications.

Monitoring Summary

Important distinction: An antimicrobial effect in a laboratory plate, a change in immune-cell migration, or improved wound closure in an experimental model does not establish systemic infection treatment or clinically useful immune enhancement.

Overall research conclusion: LL-37 is the major human cathelicidin antimicrobial peptide, with well-established roles in innate immune defense, microbial interactions, epithelial signaling, and inflammation. Laboratory and animal research demonstrates substantial biological activity, and two randomized human programs have evaluated topical LL-37 in hard-to-heal venous leg ulcers. The initial small trial reported encouraging results at selected concentrations, but the larger phase IIb trial did not achieve significant efficacy in its overall study population. Exploratory findings in larger ulcers warrant further controlled research. LL-37 can also contribute to pathological immune activation, particularly in psoriasis and rosacea-related pathways, and FDA has identified additional concerns involving immunogenicity, reproductive biology, and potentially harmful tumor-related effects in some experimental systems. LL-37 is therefore best characterized as a multifunctional investigational host-defense peptide with meaningful topical clinical research but no validated systemic therapeutic regimen.